These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19042984)

  • 41. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
    Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
    Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
    J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor markers in testis cancer.
    Klein EA
    Urol Clin North Am; 1993 Feb; 20(1):67-73. PubMed ID: 7679533
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer.
    Chang YT; Huang MY; Yeh YS; Huang CW; Tsai HL; Cheng TL; Wang JY
    PLoS One; 2016; 11(10):e0163264. PubMed ID: 27701415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early detection and prognosis of ovarian cancer using serum YKL-40.
    Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
    J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of tumor markers in gynecologic oncology.
    Olt G; Berchuck A; Bast RC
    Obstet Gynecol Surv; 1990 Sep; 45(9):570-7. PubMed ID: 1697940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site.
    Brown RW; Campagna LB; Dunn JK; Cagle PT
    Am J Clin Pathol; 1997 Jan; 107(1):12-9. PubMed ID: 8980361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer.
    Neal CE; Meis LC
    Semin Nucl Med; 1994 Oct; 24(4):272-85. PubMed ID: 7817200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Role of general practitioners in cancer screening: A survey in the French armed forces].
    Bellier T; Vallard A; Espenel S; Langrand-Escure J; Ben Mrad M; Védrine L; Magné N; Chargari C
    Bull Cancer; 2015 Dec; 102(12):993-1001. PubMed ID: 26628076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range.
    Wu TL; Zhang D; Chia JH; Tsao K-; Sun CF; Wu JT
    Clin Chim Acta; 2002 Jul; 321(1-2):77-87. PubMed ID: 12031596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Field trial for the early detection of patients with ovarian cancer].
    Kobayashi H; Terao T
    Rinsho Byori; 1992 Feb; 40(2):139-45. PubMed ID: 1374818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    Duffy MJ; Walsh S; McDermott EW; Crown J
    Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Grubb RL; Pinsky P; Prorok PC; Andriole GL
    Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review.
    Laraib U; Sargazi S; Rahdar A; Khatami M; Pandey S
    Int J Biol Macromol; 2022 Jan; 195():356-383. PubMed ID: 34920057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays.
    Filella X; Ballesta AM; Fox M; Mitchell H; Molina R; Pürstner P; Thome H
    Int J Biol Markers; 1996; 11(1):40-5. PubMed ID: 8740641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Focused Decision Support: a Data Mining Tool to Query the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dataset and Guide Screening Management for the Individual Patient.
    Sharma A; Hostetter J; Morrison J; Wang K; Siegel E
    J Digit Imaging; 2016 Apr; 29(2):160-4. PubMed ID: 26385814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical application of tumour markers: a review.
    Amayo AA; Kuria JG
    East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.